Xoma Profile

XOMA Ltd. is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis. For the three months ended 31 March 2006, Xoma Limited's revenues increased 87% to $5.6M. Net loss totaled $20.6M, vs. an income of $30.1M. Revenues reflect higher contract revenues due to increased contract manufacturing services performed under the contract with the National Institute of Allergy & Infectious Diseases("NIAID"). Net loss reflects increased research & development expenses and higher general & administrative expenses.